9INTRODUCTION: Neoadjuvant hormonal therapy is generally considered a valid option for hormone receptor positive breast cancer (BC) patients who are unfit for chemotherapy or surgery. AIMS: Whilst numerous studies analyzed efficacy of neoadjuvant chemotherapy (CT) or endocrine therapy (HT) alone in hormone receptor positive patients, there is a lack of research looking at the usefulness of a preoperative combinatorial approach of CT and HT in this patient subgroup. METHODS: Using a predictive model previously described in the literature, developed to analyze the probability of benefit from preoperative chemotherapy, we were able to compare pathological complete response (pCR) rates expected with the use of CT alone with the pCR rates r...
Aims: Recommended principles for the choice of therapies in operable breast cancer include the recog...
Introduction: The role of neoadjuvant endocrine therapy for resectable breast cancer is not well est...
Background: The integration of residual cancer burden (RCB) and post-treatment Ki67 as residual prol...
Pathologic complete response (pCR) was noted to be prognostic in all but hormone receptor-positive (...
Objective: According to the guidelines for metastatic breast cancer, hormone therapy for hormone rec...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139969/1/jso24721.pdfhttps://deepblue....
Pathological complete response (pCR) to neoadjuvant treatment correlates with outcome in breast canc...
In locally advanced (LA) breast cancer (BC), neoadjuvant treatments have led to major achievements, ...
Purpose: The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is...
Purpose: Patients with bilateral breast cancer (BBC) are usually excluded from participating in clin...
BACKGROUND AND AIMS: Locally advanced breast carcinoma is a diverse and heterogeneous group of brea...
PURPOSE:Neoadjuvant chemotherapy (NCT) is typically the initial treatment for non-early breast cance...
Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, tha...
PURPOSE: The objective of neoadjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC) ...
Pathological complete response (pCR) is the ultimate response in breast cancer patients treated with...
Aims: Recommended principles for the choice of therapies in operable breast cancer include the recog...
Introduction: The role of neoadjuvant endocrine therapy for resectable breast cancer is not well est...
Background: The integration of residual cancer burden (RCB) and post-treatment Ki67 as residual prol...
Pathologic complete response (pCR) was noted to be prognostic in all but hormone receptor-positive (...
Objective: According to the guidelines for metastatic breast cancer, hormone therapy for hormone rec...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139969/1/jso24721.pdfhttps://deepblue....
Pathological complete response (pCR) to neoadjuvant treatment correlates with outcome in breast canc...
In locally advanced (LA) breast cancer (BC), neoadjuvant treatments have led to major achievements, ...
Purpose: The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is...
Purpose: Patients with bilateral breast cancer (BBC) are usually excluded from participating in clin...
BACKGROUND AND AIMS: Locally advanced breast carcinoma is a diverse and heterogeneous group of brea...
PURPOSE:Neoadjuvant chemotherapy (NCT) is typically the initial treatment for non-early breast cance...
Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, tha...
PURPOSE: The objective of neoadjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC) ...
Pathological complete response (pCR) is the ultimate response in breast cancer patients treated with...
Aims: Recommended principles for the choice of therapies in operable breast cancer include the recog...
Introduction: The role of neoadjuvant endocrine therapy for resectable breast cancer is not well est...
Background: The integration of residual cancer burden (RCB) and post-treatment Ki67 as residual prol...